The tyrosine kinase inhibitor lapatinib is a commonly used chemotherapy drug for HER-2+ breast cancer patients, which can induce iron accumulation and ferroptosis by increasing the expression of transferrin receptor 1 (TFR1) in cancer cells, inhibiting brain metastasis of cancer tissues (91). This evidence concerns the gene ERBB2 and breast carcinoma.